144 related articles for article (PubMed ID: 21507636)
1. A novel series of piperazinyl-pyridine ureas as antagonists of the purinergic P2Y12 receptor.
Bach P; Boström J; Brickmann K; van Giezen JJ; Hovland R; Petersson AU; Ray A; Zetterberg F
Bioorg Med Chem Lett; 2011 May; 21(10):2877-81. PubMed ID: 21507636
[TBL] [Abstract][Full Text] [Related]
2. Piperazinyl-glutamate-pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation.
Parlow JJ; Burney MW; Case BL; Girard TJ; Hall KA; Hiebsch RR; Huff RM; Lachance RM; Mischke DA; Rapp SR; Woerndle RS; Ennis MD
Bioorg Med Chem Lett; 2009 Aug; 19(16):4657-63. PubMed ID: 19604694
[TBL] [Abstract][Full Text] [Related]
3. Combined 3D-QSAR, molecular docking, and molecular dynamics study on piperazinyl-glutamate-pyridines/pyrimidines as potent P2Y12 antagonists for inhibition of platelet aggregation.
Hao M; Li Y; Wang Y; Yan Y; Zhang S; Li G; Yang L
J Chem Inf Model; 2011 Oct; 51(10):2560-72. PubMed ID: 21923153
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, structure-property relationships and pharmacokinetic evaluation of ethyl 6-aminonicotinate sulfonylureas as antagonists of the P2Y₁₂ receptor.
Bach P; Boström J; Brickmann K; van Giezen JJ; Groneberg RD; Harvey DM; O'Sullivan M; Zetterberg F
Eur J Med Chem; 2013 Jul; 65():360-75. PubMed ID: 23747805
[TBL] [Abstract][Full Text] [Related]
5. Identification of high-affinity P2Y₁₂ antagonists based on a phenylpyrazole glutamic acid piperazine backbone.
Zech G; Hessler G; Evers A; Weiss T; Florian P; Just M; Czech J; Czechtizky W; Görlitzer J; Ruf S; Kohlmann M; Nazaré M
J Med Chem; 2012 Oct; 55(20):8615-29. PubMed ID: 22984835
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of ticagrelor derivatives as novel antiplatelet agents.
Zhang H; Liu J; Zhang L; Kong L; Yao H; Sun H
Bioorg Med Chem Lett; 2012 Jun; 22(11):3598-602. PubMed ID: 22546677
[TBL] [Abstract][Full Text] [Related]
7. II. SAR studies of pyridyl-piperazinyl-piperidine derivatives as CXCR3 chemokine antagonists.
Shao Y; Anilkumar GN; Carroll CD; Dong G; Hall JW; Hobbs DW; Jiang Y; Jenh CH; Kim SH; Kozlowski JA; McGuinness BF; Rosenblum SB; Schulman I; Shih NY; Shu Y; Wong MK; Yu W; Zawacki LG; Zeng Q
Bioorg Med Chem Lett; 2011 Mar; 21(5):1527-31. PubMed ID: 21277198
[TBL] [Abstract][Full Text] [Related]
8. Piperazinyl glutamate pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation.
Parlow JJ; Burney MW; Case BL; Girard TJ; Hall KA; Harris PK; Hiebsch RR; Huff RM; Lachance RM; Mischke DA; Rapp SR; Woerndle RS; Ennis MD
J Med Chem; 2010 Mar; 53(5):2010-37. PubMed ID: 20141147
[TBL] [Abstract][Full Text] [Related]
9. Optimization of ketone-based P2Y(12) receptor antagonists as antithrombotic agents: pharmacodynamics and receptor kinetics considerations.
Giordanetto F; Bach P; Zetterberg F; Antonsson T; Bylund R; Johansson J; Sellén M; Brown D; Hideståhl L; Berntsson P; Hovdal D; Zachrisson H; Björkman JA; van Giezen JJ
Bioorg Med Chem Lett; 2014 Jul; 24(13):2963-8. PubMed ID: 24835983
[TBL] [Abstract][Full Text] [Related]
10. BF0801, a novel adenine derivative, inhibits platelet activation via phosphodiesterase inhibition and P2Y12 antagonism.
Zhang S; Hu L; Du H; Guo Y; Zhang Y; Niu H; Jin J; Zhang J; Liu J; Zhang X; Kunapuli SP; Ding Z
Thromb Haemost; 2010 Oct; 104(4):845-57. PubMed ID: 20806121
[TBL] [Abstract][Full Text] [Related]
11. Part II: piperazinyl-glutamate-pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation.
Parlow JJ; Burney MW; Case BL; Girard TJ; Hall KA; Harris PK; Hiebsch RR; Huff RM; Lachance RM; Mischke DA; Rapp SR; Woerndle RS; Ennis MD
Bioorg Med Chem Lett; 2010 Feb; 20(4):1388-94. PubMed ID: 20097563
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of piperazinyl carbamates and ureas as fatty acid amide hydrolase (FAAH) and transient receptor potential (TRP) channel dual ligands.
Morera E; De Petrocellis L; Morera L; Moriello AS; Ligresti A; Nalli M; Woodward DF; Di Marzo V; Ortar G
Bioorg Med Chem Lett; 2009 Dec; 19(23):6806-9. PubMed ID: 19875281
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and structure-activity relationship studies of novel 1-[(1-acyl-4-piperidyl)methyl]-1H-2- methylimidazo[4,5-c]pyridine derivatives as potent, orally active platelet-activating factor antagonists.
Carceller E; Merlos M; Giral M; Balsa D; García-Rafanell J; Forn J
J Med Chem; 1996 Jan; 39(2):487-93. PubMed ID: 8558517
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and structure-activity relationships of retro bis-aminopyrrolidine urea (rAPU) derived small-molecule antagonists of the melanin-concentrating hormone receptor-1 (MCH-R1). Part 1.
Rowbottom MW; Vickers TD; Dyck B; Grey J; Tamiya J; Zhang M; Kiankarimi M; Wu D; Dwight W; Wade WS; Schwarz D; Heise CE; Madan A; Fisher A; Petroski R; Goodfellow VS
Bioorg Med Chem Lett; 2006 Sep; 16(17):4450-7. PubMed ID: 16814542
[TBL] [Abstract][Full Text] [Related]
15. N-Arylalkylpiperidine urea derivatives as CC chemokine receptor-3 (CCR3) antagonists.
Batt DG; Houghton GC; Roderick J; Santella JB; Wacker DA; Welch PK; Orlovsky YI; Wadman EA; Trzaskos JM; Davies P; Decicco CP; Carter PH
Bioorg Med Chem Lett; 2005 Feb; 15(3):787-91. PubMed ID: 15664858
[TBL] [Abstract][Full Text] [Related]
16. Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (prasugrel, LY640315), a novel P2Y12 receptor inhibitor.
Hasegawa M; Sugidachi A; Ogawa T; Isobe T; Jakubowski JA; Asai F
Thromb Haemost; 2005 Sep; 94(3):593-8. PubMed ID: 16268477
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and biological evaluation of 2-(phenoxyaryl)-3-urea derivatives as novel P2Y
Peng J; Zhao L; Wang L; Chen H; Qiu Y; Wang J; Yang H; Liu J; Liu H
Eur J Med Chem; 2018 Oct; 158():302-310. PubMed ID: 30223118
[TBL] [Abstract][Full Text] [Related]
18. III. Identification of novel CXCR3 chemokine receptor antagonists with a pyrazinyl-piperazinyl-piperidine scaffold.
Kim SH; Anilkumar GN; Zawacki LG; Zeng Q; Yang DY; Shao Y; Dong G; Xu X; Yu W; Jiang Y; Jenh CH; Hall JW; Carroll CD; Hobbs DW; Baldwin JJ; McGuinness BF; Rosenblum SB; Kozlowski JA; Shankar BB; Shih NY
Bioorg Med Chem Lett; 2011 Dec; 21(23):6982-6. PubMed ID: 22018463
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor.
Dobesh PP
Pharmacotherapy; 2009 Sep; 29(9):1089-102. PubMed ID: 19698014
[TBL] [Abstract][Full Text] [Related]
20. Tetrahydro-4-quinolinamines identified as novel P2Y(1) receptor antagonists.
Morales-Ramos AI; Mecom JS; Kiesow TJ; Graybill TL; Brown GD; Aiyar NV; Davenport EA; Kallal LA; Knapp-Reed BA; Li P; Londregan AT; Morrow DM; Senadhi S; Thalji RK; Zhao S; Burns-Kurtis CL; Marino JP
Bioorg Med Chem Lett; 2008 Dec; 18(23):6222-6. PubMed ID: 18926700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
